What the FDA labels say about taking them together
Alfuzosin and nelfinavir
Nelfinavir's FDA label of December 11, 2025 names alfuzosin in its contraindications section; the alfuzosin label PlainMeds reads does not name nelfinavir. The nelfinavir label: “Potentially increased alfuzosin concentrations can result in hypotension.”
Check it at the source: the alfuzosin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.); the nelfinavir FDA label on DailyMed (effective December 11, 2025, AGOURON).
What does the alfuzosin label say about nelfinavir?
Alfuzosin's label (effective December 5, 2024) does not name nelfinavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Uroxatral), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set 9fc7f119-f36b-44cf-945d-940160f3afe3), via openFDA; the full label on DailyMed
What does the nelfinavir label say about alfuzosin?
Nelfinavir label, contraindicationsDrug Class: Alpha 1-adrenoreceptor antagonist; Drugs Within Class That Are Contraindicated With VIRACEPT: Alfuzosin; Clinical Comment: Potentially increased alfuzosin concentrations can result in hypotension.
Source: FDA drug label (VIRACEPT), AGOURON, effective December 11, 2025 (SPL set e72c2bc6-9462-4a2e-8e1d-b97592376cbd), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Alfuzosin | Nelfinavir | |
|---|---|---|
| Labeled for | Enlarged prostate (BPH) | HIV |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.105 per tablet 10 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once